Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
51
ZBIO Quote, Financials, Valuation and Earnings
Last price:
$38.11
Seasonality move
:
-4.38%
Day range:
$34.50 - $36.91
52-week range:
$5.83 - $41.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
102.44x
P/B ratio:
7.81x
Volume:
186.6K
Avg. volume:
486.5K
1-year change:
241.75%
Market cap:
$1.5B
Revenue:
$5M
EPS (TTM):
-$4.53
Analysts' Opinion
-
Consensus RatingZenas BioPharma, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $45.00, Zenas BioPharma, Inc. has an estimated upside of 22.72% from its current price of $36.67.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $36.00 representing 100% downside risk from its current price of $36.67.
Fair Value
-
According to the consensus of 7 analysts, Zenas BioPharma, Inc. has 22.72% upside to fair value with a price target of $45.00 per share.
ZBIO vs. S&P 500
-
Over the past 5 trading days, Zenas BioPharma, Inc. has underperformed the S&P 500 by -8.01% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Zenas BioPharma, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Zenas BioPharma, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Zenas BioPharma, Inc. reported revenues of --.
Earnings Growth
-
Zenas BioPharma, Inc. has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Zenas BioPharma, Inc. reported earnings per share of -$1.22.
Enterprise value:
1.2B
EV / Invested capital:
6.31x
Price / LTM sales:
102.44x
EV / EBIT:
--
EV / Revenue:
82.93x
PEG ratio (5yr expected):
-0.05x
EV / Free cash flow:
-7.85x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$14.9M
Return On Assets:
-55.13%
Net Income Margin (TTM):
-1265.99%
Return On Equity:
-68.2%
Return On Invested Capital:
-67.98%
Operating Margin:
-373.3%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $50M | $15M | -- | -- | |
| Gross Profit | $49.9M | $49.9M | $14.9M | -$36K | -$11K | |
| Operating Income | -$21.4M | -$72.6M | -$195.7M | -$41M | -$47.6M | |
| EBITDA | -$21.2M | -$72.5M | -$195.6M | -$40.9M | -$47.6M | |
| Diluted EPS | -$0.40 | -$1.79 | -$4.53 | -$0.92 | -$1.22 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $76.7M | $393.8M | $296.6M | |
| Total Assets | -- | -- | $83.8M | $403.4M | $322M | |
| Current Liabilities | -- | -- | $15.6M | $44M | $52.4M | |
| Total Liabilities | -- | -- | $286M | $44M | $125.6M | |
| Total Equity | -- | -- | -$202.2M | $359.4M | $196.4M | |
| Total Debt | -- | -- | -- | -- | $180K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$96.5M | -$158.5M | -$31.1M | -$41.1M | |
| Cash From Investing | -- | -$26.8M | -$162.3M | -$26.8M | $40M | |
| Cash From Financing | -- | $411.2M | $76.3M | $234M | $72.6M | |
| Free Cash Flow | -- | -$96.5M | -$158.6M | -$31.1M | -$41.1M | |
ZBIO
Sector
Market Cap
$1.5B
$28.4M
Price % of 52-Week High
89.44%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-0.3%
-1.32%
1-Year Price Total Return
241.75%
-22.19%
Beta (5-Year)
--
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$37.69
200-day SMA
Buy
Level
$16.20
Bollinger Bands (100)
Buy
Level
15.39 - 30.95
Chaikin Money Flow
Buy
Level
1.2M
20-day SMA
Buy
Level
$35.82
Relative Strength Index (RSI14)
Buy
Level
56.48
ADX Line
Sell
Level
15.29
Williams %R
Neutral
Level
-54.125
50-day SMA
Buy
Level
$29.45
MACD (12, 26)
Buy
Level
8.34
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
1.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.6254)
Sell
CA Score
(Annual)
Level (-2.5955)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (4.1256)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
Stock Forecast FAQ
In the current month, ZBIO has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ZBIO average analyst price target in the past 3 months is $45.00.
-
Where Will Zenas BioPharma, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Zenas BioPharma, Inc. share price will rise to $45.00 per share over the next 12 months.
-
What Do Analysts Say About Zenas BioPharma, Inc.?
Analysts are divided on their view about Zenas BioPharma, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Zenas BioPharma, Inc. is a Sell and believe this share price will drop from its current level to $36.00.
-
What Is Zenas BioPharma, Inc.'s Price Target?
The price target for Zenas BioPharma, Inc. over the next 1-year time period is forecast to be $45.00 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ZBIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Zenas BioPharma, Inc. is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ZBIO?
You can purchase shares of Zenas BioPharma, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Zenas BioPharma, Inc. shares.
-
What Is The Zenas BioPharma, Inc. Share Price Today?
Zenas BioPharma, Inc. was last trading at $38.11 per share. This represents the most recent stock quote for Zenas BioPharma, Inc.. Yesterday, Zenas BioPharma, Inc. closed at $36.67 per share.
-
How To Buy Zenas BioPharma, Inc. Stock Online?
In order to purchase Zenas BioPharma, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ZBIO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ZBIO
Sector
P/E ratio
--
23.66x
PEG ratio
-0.05x
-0.01x
P/B ratio
7.81x
1.84x
Price / LTM sales
102.44x
1.60x
Growth Metrics
ZBIO
Sector
Revenue growth
--
4.85%
Earnings growth
-32.2%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.85
-$0.20
Profitability
ZBIO
Sector
Profitability FY 2024
$4.9M
$3.6M
Return on invested capital
-67.98%
-30.98%
Return on assets
-55.13%
-27.62%
Return on equity
-68.2%
-36.69%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
17
Estimated Next Earnings Date
Feb
11
Balance Sheet
ZBIO
Sector
Total cash
$290.9M
$27.2M
Short term investments
$31M
$25.7M
Total assets
$370M
$79.9M
Long term debt
$180K
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
65
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
